|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 45/06 | (2013.01) |
| A61K 31/10 | (2006.01) | ||
| A61K 31/445 | (2006.01) | ||
| A61K 31/196 | (2013.01) | ||
| A61K 31/407 | (2013.01) | ||
| A61K 31/473 | (2006.01) | ||
| A61K 31/4545 | (2013.01) | ||
| A61K 31/60 | (2006.01) | ||
| A61K 31/495 | (2013.01) | ||
| A61K 45/06 | (2006.01) | ||
| A61K 9/00 | (2006.01) | ||
| A61K 31/60 | (2013.01) | ||
| A61K 31/603 | (2013.01) | ||
| A61K 31/192 | (2006.01) | ||
| A61K 31/445 | (2013.01) | ||
| A61K 31/196 | (2006.01) | ||
| A61K 31/192 | (2013.01) | ||
| A61K 31/407 | (2006.01) | ||
| A61K 9/0056 | (2013.01) | ||
| A61P 1/02 | (2006.01) | ||
| A61P 1/02 | (2018.01) | ||
| A61P 3/02 | (2006.01) | ||
| A61P 29/00 | (2018.01) | ||
| A61P 29/00 | (2006.01) | ||
| A61P 3/02 | (2018.01) | ||
| A61P 39/02 | (2006.01) | ||
| A61P 39/02 | (2018.01) | ||
| A61P 43/00 | (2006.01) | ||
| A61P 43/00 | (2018.01) | ||
| A61K 31/4545 | (2006.01) | ||
| A61K 31/495 | (2006.01) | ||
| A61K 31/603 | (2006.01) |
| (11) | Number of the document | 3273952 |
| (13) | Kind of document | T |
| (96) | European patent application number | 16769429.8 |
| Date of filing the European patent application | 2016-03-18 | |
| (97) | Date of publication of the European application | 2018-01-31 |
| (45) | Date of publication and mention of the grant of the patent | 2022-06-15 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2016/023200 |
| Date | 2016-03-18 |
| (87) | Number | WO 2016/154028 |
| Date | 2016-09-29 |
| (30) | Number | Date | Country code |
| 201562138665 P | 2015-03-26 | US |
| (72) |
IVERSEN, Jacqueline M. , US
IVERSEN, James M. , US
|
| (73) |
Sen-Jam Pharmaceutical LLC ,
223 Wall Street 130, Huntington, New York 11743,
US
|
| (54) | COMBINATION OF NAPROXEN AND FEXOFENADINE TO INHIBIT SYMPTOMS ASSOCIATED WITH VEISALGIA |
| COMBINATION OF NAPROXEN AND FEXOFENADINE TO INHIBIT SYMPTOMS ASSOCIATED WITH VEISALGIA |